Scinai Immunotherapeutics completed the acquisition of Recipharm Israel from Recipharm.

Scinai Immunotherapeutics, a biopharmaceutical company developing inflammation and immunology therapeutics and operating a growing CDMO business, completed the acquisition of Recipharm Israel, a CDMO company specializing on small molecule API development and manufacturing, from Recipharm, a contract development and manufacture of pharmaceuticals company. Financial terms were not disclosed. "This transaction fundamentally strengthens Scinai's CDMO platform. By combining our early-stage development strengths with Recipharm Israel's manufacturing capabilities and Recipharm's global footprint, we are creating a differentiated offering that supports clients from early development through commercialization. Importantly, the collaboration allows Scinai to participate in the long-term success of client programs while maintaining capital discipline and operational focus," Amir Reichman, Scinai Chief Executive Officer.